6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cross-talk between red blood cells and plasma influences blood flow and omics phenotypes in severe COVID-19

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Coronavirus disease 2019 (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can affect multiple organs, among which is the circulatory system. Inflammation and mortality risk markers were previously detected in COVID-19 plasma and red blood cells (RBCs) metabolic and proteomic profiles. Additionally, biophysical properties, such as deformability, were found to be changed during the infection. Based on such data, we aim to better characterize RBC functions in COVID-19. We evaluate the flow properties of RBCs in severe COVID-19 patients admitted to the intensive care unit by using microfluidic techniques and automated methods, including artificial neural networks, for an unbiased RBC analysis. We find strong flow and RBC shape impairment in COVID-19 samples and demonstrate that such changes are reversible upon suspension of COVID-19 RBCs in healthy plasma. Vice versa, healthy RBCs resemble COVID-19 RBCs when suspended in COVID-19 plasma. Proteomics and metabolomics analyses allow us to detect the effect of plasma exchanges on both plasma and RBCs and demonstrate a new role of RBCs in maintaining plasma equilibria at the expense of their flow properties. Our findings provide a framework for further investigations of clinical relevance for therapies against COVID-19 and possibly other infectious diseases.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A new coronavirus associated with human respiratory disease in China

          Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health 1–3 . Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty. A severe respiratory disease was recently reported in Wuhan, Hubei province, China. As of 25 January 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 December 2019. Epidemiological investigations have suggested that the outbreak was associated with a seafood market in Wuhan. Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 December 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough. Metagenomic RNA sequencing 4 of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here ‘WH-Human 1’ coronavirus (and has also been referred to as ‘2019-nCoV’). Phylogenetic analysis of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China 5 . This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            COVID-19: consider cytokine storm syndromes and immunosuppression

            As of March 12, 2020, coronavirus disease 2019 (COVID-19) has been confirmed in 125 048 people worldwide, carrying a mortality of approximately 3·7%, 1 compared with a mortality rate of less than 1% from influenza. There is an urgent need for effective treatment. Current focus has been on the development of novel therapeutics, including antivirals and vaccines. Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome. We recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality. Current management of COVID-19 is supportive, and respiratory failure from acute respiratory distress syndrome (ARDS) is the leading cause of mortality. 2 Secondary haemophagocytic lymphohistiocytosis (sHLH) is an under-recognised, hyperinflammatory syndrome characterised by a fulminant and fatal hypercytokinaemia with multiorgan failure. In adults, sHLH is most commonly triggered by viral infections 3 and occurs in 3·7–4·3% of sepsis cases. 4 Cardinal features of sHLH include unremitting fever, cytopenias, and hyperferritinaemia; pulmonary involvement (including ARDS) occurs in approximately 50% of patients. 5 A cytokine profile resembling sHLH is associated with COVID-19 disease severity, characterised by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α. 6 Predictors of fatality from a recent retrospective, multicentre study of 150 confirmed COVID-19 cases in Wuhan, China, included elevated ferritin (mean 1297·6 ng/ml in non-survivors vs 614·0 ng/ml in survivors; p 39·4°C 49 Organomegaly None 0 Hepatomegaly or splenomegaly 23 Hepatomegaly and splenomegaly 38 Number of cytopenias * One lineage 0 Two lineages 24 Three lineages 34 Triglycerides (mmol/L) 4·0 mmol/L 64 Fibrinogen (g/L) >2·5 g/L 0 ≤2·5 g/L 30 Ferritin ng/ml 6000 ng/ml 50 Serum aspartate aminotransferase <30 IU/L 0 ≥30 IU/L 19 Haemophagocytosis on bone marrow aspirate No 0 Yes 35 Known immunosuppression † No 0 Yes 18 The Hscore 11 generates a probability for the presence of secondary HLH. HScores greater than 169 are 93% sensitive and 86% specific for HLH. Note that bone marrow haemophagocytosis is not mandatory for a diagnosis of HLH. HScores can be calculated using an online HScore calculator. 11 HLH=haemophagocytic lymphohistiocytosis. * Defined as either haemoglobin concentration of 9·2 g/dL or less (≤5·71 mmol/L), a white blood cell count of 5000 white blood cells per mm3 or less, or platelet count of 110 000 platelets per mm3 or less, or all of these criteria combined. † HIV positive or receiving longterm immunosuppressive therapy (ie, glucocorticoids, cyclosporine, azathioprine).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

              Abstract Background In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronavirus pneumonia (NCP) cases were a concern. Objectives To describe the coagulation feature of patients with NCP. Methods Conventional coagulation results and outcomes of 183 consecutive patients with confirmed NCP in Tongji hospital were retrospectively analyzed. Results The overall mortality was 11.5%, the non‐survivors revealed significantly higher D‐dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time compared to survivors on admission (P < .05); 71.4% of non‐survivors and 0.6% survivors met the criteria of disseminated intravascular coagulation during their hospital stay. Conclusions The present study shows that abnormal coagulation results, especially markedly elevated D‐dimer and FDP are common in deaths with NCP.
                Bookmark

                Author and article information

                Contributors
                Role: Reviewing Editor
                Role: Senior Editor
                Journal
                eLife
                Elife
                eLife
                eLife
                eLife Sciences Publications, Ltd
                2050-084X
                20 December 2022
                2022
                20 December 2022
                : 11
                : e81316
                Affiliations
                [1 ] Dynamics of Fluids, Department of Experimental Physics, Saarland University ( https://ror.org/01jdpyv68) Saarbrücken Germany
                [2 ] Institute for Clinical and Experimental Surgery, Campus University Hospital, Saarland University ( https://ror.org/01jdpyv68) Homburg Germany
                [3 ] Cysmic GmbH Saarbrücken Germany
                [4 ] Department of Biochemistry and Molecular Genetics, University of Colorado Denver ( https://ror.org/02hh7en24) Aurora United States
                [5 ] Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg ( https://ror.org/03pvr2g57) Wuerzburg Germany
                [6 ] Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt ( https://ror.org/03f6n9m15) Frankfurt Germany
                [7 ] Fraunhofer Institute for Translational Medicine and Pharmacology ITMP ( https://ror.org/01s1h3j07) Frankfurt Germany
                [8 ] Department of Physics and Materials Science, University of Luxembourg ( https://ror.org/036x5ad56) Luxembourg City Luxembourg
                [9 ] Theoretical Medicine and Biosciences, Campus University Hospital, Saarland University ( https://ror.org/01jdpyv68) Homburg Germany
                The Ohio State University ( https://ror.org/00rs6vg23) United States
                Icahn School of Medicine at Mount Sinai ( https://ror.org/04a9tmd77) United States
                The Ohio State University ( https://ror.org/00rs6vg23) United States
                The Ohio State University ( https://ror.org/00rs6vg23) United States
                University of Wisconsin-Madison ( https://ror.org/01y2jtd41) United States
                Author notes
                [†]

                These authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0003-1235-1521
                https://orcid.org/0000-0001-5452-2275
                https://orcid.org/0000-0002-9668-5504
                https://orcid.org/0000-0002-0855-9138
                https://orcid.org/0000-0002-2666-8696
                https://orcid.org/0000-0002-0212-9110
                https://orcid.org/0000-0002-5831-0365
                https://orcid.org/0000-0001-7788-4594
                https://orcid.org/0000-0001-6796-9535
                https://orcid.org/0000-0003-4412-7559
                Article
                81316
                10.7554/eLife.81316
                9767455
                36537079
                ca64e674-11b4-445b-805d-e6d4d4ffe2e0
                © 2022, Recktenwald, Simionato et al

                This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

                History
                : 22 June 2022
                : 27 November 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100010661, Horizon 2020 Framework Programme;
                Award ID: 860436
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001659, Deutsche Forschungsgemeinschaft;
                Award ID: WA 1336/13-1
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100005690, Universität des Saarlandes;
                Award ID: Open Access Publication Funding
                Award Recipient :
                The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.
                Categories
                Research Article
                Cell Biology
                Physics of Living Systems
                Custom metadata
                For severe COVID-19 patients' red blood cells, healthy donor plasma reduces pathological red blood cell shape alterations and improves microcapillary flow in vitro through an interaction between red blood cells and plasma.

                Life sciences
                red blood cells,covid-19,microfluidics,omics,blood,human
                Life sciences
                red blood cells, covid-19, microfluidics, omics, blood, human

                Comments

                Comment on this article